Baike Biotech initiates Phase I clinical trial of HSV-2 mRNA vaccine.

According to the "Beyo Biotechnology" WeChat public account, on September 9th, Beyo Biotechnology successfully held a launch meeting for the Phase I dose escalation trial of the HSV-2 mRNA vaccine in subjects aged 18-55 with different serological infections at Jishuitan Hospital in Beijing. The launch meeting focused on systematic training and work deployment of core contents such as genital herpes disease and vaccine research background, GCP regulations, clinical trial protocol, investigator manual, sample management, and on-site procedures. Subsequently, all work preparations are in order, and the subject enrollment work is about to begin comprehensively.